InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,726.50
(
0.14%
)
US TECH 100
19,411.20
(
0.46%
)
Dow Jones
42,128.87
(
0.01%
)
Brent Oil
74.31
(
0.77%
)
Bitcoin
63,590.55
(
0.42%
)
Post# of 253207
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

dewophile

Send PM Follow Ignore
Followers 47
Posts 4694
Boards Moderated 0
Alias Born 07/19/2006

dewophile

Re: None

Tuesday, 05/21/2019 8:46:29 AM

Tuesday, May 21, 2019 8:46:29 AM

Post# of 253207
ARRY

Interim data in braf mutant CRC is positive, but not as robust as the safety lead in. May not be superior to other Braf inhibitors in this indication on efficacy so not a home run. I still think will be the leading braf/mek in this indication as tolerability better than other combos and they should get on label (and already are in NCCN guidelines):

http://investor.arraybiopharma.com/news-releases/news-release-details/array-biopharma-announces-braftovi-mektovi-cetuximab-meet
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up